334 related articles for article (PubMed ID: 36451660)
21. PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.
Diaz-Flores E; Goldschmidt H; Depeille P; Ng V; Akutagawa J; Krisman K; Crone M; Burgess MR; Williams O; Houseman B; Shokat K; Sampath D; Bollag G; Roose JP; Braun BS; Shannon K
Sci Signal; 2013 Dec; 6(304):ra105. PubMed ID: 24300897
[TBL] [Abstract][Full Text] [Related]
22. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
Nakayama N; Nakayama K; Yeasmin S; Ishibashi M; Katagiri A; Iida K; Fukumoto M; Miyazaki K
Br J Cancer; 2008 Dec; 99(12):2020-8. PubMed ID: 19018267
[TBL] [Abstract][Full Text] [Related]
23. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
Fritsche-Guenther R; Witzel F; Kempa S; Brummer T; Sers C; Blüthgen N
Oncotarget; 2016 Feb; 7(7):7960-9. PubMed ID: 26799289
[TBL] [Abstract][Full Text] [Related]
24. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
25. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
Ji Z; Mei FC; Xie J; Cheng X
J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
[TBL] [Abstract][Full Text] [Related]
27. Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells.
Nicke B; Bastien J; Khanna SJ; Warne PH; Cowling V; Cook SJ; Peters G; Delpuech O; Schulze A; Berns K; Mullenders J; Beijersbergen RL; Bernards R; Ganesan TS; Downward J; Hancock DC
Mol Cell; 2005 Dec; 20(5):673-85. PubMed ID: 16337592
[TBL] [Abstract][Full Text] [Related]
28. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
29. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
30. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
[TBL] [Abstract][Full Text] [Related]
31. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
32. The possible roles of B-cell novel protein-1 (BCNP1) in cellular signalling pathways and in cancer.
Patel SJ; Trivedi GL; Darie CC; Clarkson BD
J Cell Mol Med; 2017 Mar; 21(3):456-466. PubMed ID: 27680505
[TBL] [Abstract][Full Text] [Related]
33. Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells.
Aksamitiene E; Achanta S; Kolch W; Kholodenko BN; Hoek JB; Kiyatkin A
Cell Signal; 2011 Nov; 23(11):1794-805. PubMed ID: 21726627
[TBL] [Abstract][Full Text] [Related]
34. BRAFV600E: implications for carcinogenesis and molecular therapy.
Cantwell-Dorris ER; O'Leary JJ; Sheils OM
Mol Cancer Ther; 2011 Mar; 10(3):385-94. PubMed ID: 21388974
[TBL] [Abstract][Full Text] [Related]
35. Protein kinase C delta is required for survival of cells expressing activated p21RAS.
Xia S; Forman LW; Faller DV
J Biol Chem; 2007 May; 282(18):13199-210. PubMed ID: 17350960
[TBL] [Abstract][Full Text] [Related]
36. Signaling through mitogen-activated protein kinase and Rac/Rho does not duplicate the effects of activated Ras on skeletal myogenesis.
Ramocki MB; Johnson SE; White MA; Ashendel CL; Konieczny SF; Taparowsky EJ
Mol Cell Biol; 1997 Jul; 17(7):3547-55. PubMed ID: 9199290
[TBL] [Abstract][Full Text] [Related]
37. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991
[TBL] [Abstract][Full Text] [Related]
38. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
[TBL] [Abstract][Full Text] [Related]
39. AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.
Ho C; Wang C; Mattu S; Destefanis G; Ladu S; Delogu S; Armbruster J; Fan L; Lee SA; Jiang L; Dombrowski F; Evert M; Chen X; Calvisi DF
Hepatology; 2012 Mar; 55(3):833-45. PubMed ID: 21993994
[TBL] [Abstract][Full Text] [Related]
40. Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma.
Rajpurohit T; Bhattacharya S
Curr Mol Pharmacol; 2022; 15(7):904-928. PubMed ID: 35088684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
